Yonggang Wang

FDA investigator

Appears on 1 document from 2019, mostly at sites in Australia. Most often cites sampling and testing of in-process materials and drug products (21 CFR 211.110).

1
Documents on file
2.0
Observations per 483
2019
First seen
2019
Most recent

What they cite most

From 2 observations
  • 21 CFR 211.110
    Sampling and testing of in-process materials and drug products
    1
  • 21 CFR 600.14
    Reporting of biological product deviations by licensed manufacturers
    1

Activity by year

2019: 1

Where

Australia 1

Often inspects with

Gene D. Arcy· Scott Ballard

Is Yonggang Wang coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

1 document, newest first
FirmOpen
483 CSL Behring (Australia) Pty LtdNov 11, 2019 · Broadmeadows, Australia

About this profile

What does Yonggang Wang inspect?

Yonggang Wang appears on 1 document on file covering 1 site, mostly in Australia.

What do they cite most often?

21 CFR 211.110 (sampling and testing of in-process materials and drug products), followed by 21 CFR 600.14.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Yonggang Wang is dated Nov 11, 2019.